Partnership Opportunities

Elevate Your Services To CNS Experts

2025 continues to advance CNS drug delivery, fuelled by innovations in receptor-mediated transport, pressure-driven devices, minimally invasive CSF delivery, and next-generation targeting strategies. Yet, as unmet needs persist, crossing the blood-brain barrier, achieving precise regional targeting, and improving translational predictability, the field faces critical questions: which innovations will truly transform CNS therapeutics, and which will fall short?

Uniting 100+ senior decision-makers including from large pharma, leading biotech, and emerging start-ups, the 7th CNS Drug Delivery Summit returns to provide an unrivalled platform to stay ahead of the latest advances, showcase solutions, and tackle the industry’s most pressing CNS delivery challenges.

This December, position your company as the go-to partner for solving the industry’s toughest delivery challenges, from improving translational predictability to enabling minimally invasive local delivery.

Small group; friendly discussions. Willingness to share experiences in this very difficult field. Especially loved the speed networking.

CraniUS

The meeting brought together an interesting mix of experts in their field including neuroscientists, pharmacologists, medical engineers, academics, clinicians and business executives, all with the same goal which is to bring therapies to treat CNS diseases. It's unusual to bring such diverse expertise into a room where ideas can be exchanged freely in a relaxed atmosphere.

Neurochase

Current Partners

RealeveLogoFINALXL
Aptar_Pharma_logo_cg10_660_HighRes
Shift Bio

Experts Need Your Help To:

  • Overcome limited distribution in the CNS with delivery devices capable of pressure-driven delivery in human-sized brains
  • Improve visibility into therapeutic targeting with quantitative imaging and microscopy services to model brain distribution after local injection or BBB-crossing
  • Address the lack of clinically scalable CNS delivery methods with minimally invasive CSF delivery devices
  • Bridge the translational gap with clinically relevant rodent and animal models for measuring brain delivery and efficient dose escalation studies
  • Decrease uncertainty in PK/PD outcomes with CRO expertise in pharmacokinetics and pharmacodynamics
  • Reduce late-stage clinical failures with translatable in vitro blood-brain barrier models with greater ability to recapitulate the BBB

Why Partner?

Build & Expand Your Network:

Connect with a diverse array of C-Level industry professionals and decision makers across translation, platform development, novel modalities, DMPK, and more, to broaden your network and explore potential collaborations beyond the conference

Gain Exclusive Industry Insights:

Engage in discussions led by industry leaders to understand emerging trends, challenges, and opportunities in the CNS drug delivery space to tailor, refine, and deliver standout solutions that truly resonate

Shape the Industry Conversation:

Demonstrate thought leadership by contributing to discussions on breaking through the BBB, advancing delivery innovation, and accelerating therapeutic impact

Secure & Accelerate New Business:

Leverage exclusive Hanson Wade insights into the core CNS challenges facing biopharma, position your brand as the partner of choice, and win new business by directly aligning your solutions with customer priorities

Showcase Your Differentiation:

Put your platforms, devices, and solutions in front of a curated audience spanning the full spectrum of experts shaping the future of targeted CNS drug delivery

Who will you meet?

Seniority of Attendees Stats C-lvl: 12% Director: 26% VP: 12% Manager/Head of Department: 8% Scientist: 23 Other 19%
Type of Companies Attending Biotech: 33% Large Pharma: 28% Academic Institutions:13% Other: 7% Service Providers: 19%

Become a Partner 

Maia Sethi

Senior Partnerships Director 

sponsor@hansonwade.com

Maia Sethi (1)